In approximately 44% of melanomas, BRAF mutations are accompanied by PTEN loss, an outcome that promotes high levels of immunosuppressive elements such as myeloid-derived suppressor cells and low levels of natural killer (NK) and cytotoxic T cells. The gene discussed is BRAF; the disease is melanoma.